Arcutis Biotherapeutics, Inc. (ARQT) Misses Q1 EPS by 4c
Tweet
Share
E-mailGet Alerts ARQT Hot Sheet
Join SI Premium – FREE
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q1 EPS of ($0.09), $0.04 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $105.4 million versus the consensus estimate of $103.72 million.
For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Starts iBio, Inc. (IBIO) at Buy
- CIENA (CIEN) PT Raised to $450 at Morgan Stanley
- H.C. Wainwright Reiterates Buy Rating on Kodiak Sciences Inc. (KOD)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
